A multiple sclerosis medication is moving through the FDA process.
For people with multiple sclerosis (MS) the news of a drug that may help them overcome their illness can bring hope.
Especially those with progressive types of MS who have not found a drug that has worked to reduce flares, improve symptoms, or slow disease progression.
According to the National Multiple Sclerosis Society, 2.3 million people worldwide are living with the disease.
Now, for the first time, people with primary progressive MS (PPMS) may benefit from what officials at Roche Pharmaceuticals are calling a medical breakthrough, expected to be approved by the Food and Drug Administration (FDA) in late March.
In a large phase III trial, OCREVUS was shown to significantly slow the progression of physical disability in people with PPMS. It was also successful in two large studies at reducing attacks in people with relapsing-remitting MS (RMS), according to Roche.
Read full article: New Drug to Treat Multiple Sclerosis Awaits FDA Approval
|Read Full Article: New Drug to Treat Multiple Sclerosis Awaits FDA Approval|